Samsung Biologics listed among top most sustainable companies in Dow Jones Sustainability World Index

December 17, 2024 03:51 AM +04 | By Cision
 Samsung Biologics listed among top most sustainable companies in Dow Jones Sustainability World Index
Image source: Kalkine Media
  • Acknowledged for strong environmental, social, and governance (ESG) performance and continued commitment to sustainability through net-zero initiatives and responsible value chain management

INCHEON, South Korea, Dec. 17, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced its continued recognition by the Dow Jones Sustainability World Index (DJSI), a globally recognized benchmark for evaluating the sustainability performance of over 2,500 publicly traded companies.

Samsung Biologics was recognized for its dedication to embed sustainable business practices across its operations, particularly robust environmental efforts, including progress toward achieving net-zero emissions and an enhanced focus on carbon reduction across the value chain. The company has been listed for four consecutive years.

"This achievement demonstrates our commitment to driving sustainability across our operations and the broader biopharma value chain," said John Rim, President and CEO of Samsung Biologics. "We remain focused on delivering meaningful progress toward a net-zero future while supporting our clients and partners with their ESG goals and contribute to a healthier world."

Samsung Biologics continues to advance ESG initiatives, including its leadership role within the Sustainable Markets Initiative (SMI). As a champion of the Supply Chains Working Group in the SMI Health Systems Task Force, the company actively engages global suppliers to decarbonize and build more resilient value chains. The global CDMO is accelerating transition to renewable energy through its Power Purchase Agreement, Renewable Energy Certificate, also having completed Product Carbon Footprint measurements to support our clients in achieving net-zero. This year, Samsung Biologics joined the Pharmaceutical Supply Chain Initiative and also received an EcoVadis platinum sustainability rating.

About Samsung Biologics Co., Ltd.

Samsung Biologics (KRX: 207940.KS) is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing support for the biopharmaceutical products we manufacture. Our state-of-the-art facilities are CGMP compliant with bioreactors ranging from small to large scales to serve varying client needs. To maximize our operational efficiency and expand our capabilities in response to growing biomanufacturing demand, Samsung Biologics offers a combined 604 kL total capacity. The company launched Bio Campus II with the construction of Plant 5, which will be operational in April 2025, adding 180 kL biomanufacturing capacity. Additionally, Samsung Biologics America enables the company to work in closer proximity to clients based in the U.S. and Europe. We continue to upgrade our capabilities to accommodate our clients by investing in a dedicated antibody-drug conjugate (ADC) facility, mRNA technologies, and additional aseptic filling capacity. As a sustainable CDMO partner of choice, we are committed to on-time, in-full delivery of the products we manufacture with our flexible manufacturing solutions, operational excellence, and proven expertise.

Samsung Biologics Media Contact
Claire Kim, Head of Global Marketing Communication
[email protected] 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

Recent Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.